Plain-English translation of NCT02097706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called an NMDA receptor antagonist can help treat borderline personality disorder. The medication has been approved for Alzheimer's disease and early research suggests it may also help with other psychiatric conditions. Researchers want to see if taking this treatment for 12 weeks can reduce the emotional and behavioral symptoms that make borderline personality disorder so difficult to live with.
Borderline personality disorder is a serious condition that causes severe emotional pain and puts people at high risk for suicide. Right now, there are no medications proven to specifically treat this disorder, and many people don't do well with current treatment options. This trial exists because doctors urgently need better, faster-acting treatments to help patients.
You likely qualify if…
You likely don't qualify if…
You would take one capsule by mouth every day for 12 weeks (84 days). Half of participants will receive the active medication and half will receive a placebo (a pill with no active ingredient), chosen randomly. During the study, you would have visits to assess how you're doing and to check that the medication is safe for you. Your current psychiatric medications and therapy should stay the same during the trial.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Australia